Cited by 395Angiogenesis and VEGF in CancerCancer Mechanisms and TherapyProtease and Inhibitor Mechanisms

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases

Qian, Fawn, Engst, Stefan, Yamaguchi, Kyoko, Yu, Peiwen, Won, Kwang-Ai, Mock, Lillian, Lou, Tracy, Tan, Jenny, Li, Connie, Tam, Danny, Lougheed, Julie, Yakes, F. Michael, Bentzien, Frauke, Xu, Wei, Zaks, Tal, Wooster, Richard, Greshock, Joel, Joly, Alison H.·2009·Cancer Research

DOI 10.1158/0008-5472.can-08-4889

Published version of a preprint

Open this paper in CoChat — free account

Abstract

The Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), are overexpressed and/or activated in a wide variety of human malignancies. Vascular endothelial growth factor (VEGF) receptors are expressed on the surface of vascular endothelial cells and cooperate with Met to induce tumor invasion and vascularization. EXEL-2880 (XL880, GSK1363089) is a small-molecule kinase inhibitor that targets members of the HGF and VEGF receptor tyrosine kinase families, with additional inhibitory activity toward KIT, Flt-3, platelet-derived growth factor receptor β, and Tie-2. Binding of EXEL-2880 to Met and VEGF receptor 2 (KDR) is characterized by a very slow off-rate, consistent with X-ray crystallographic data showing that the inhibitor is deeply bound in the Met kinase active site cleft. EXEL-2880 inhibits cellular HGF-induced Met phosphorylation and VEGF-induced extracellular signal-regulated kinase phosphorylation and prevents both HGF-induced responses of tumor cells and HGF/VEGF-induced responses of endothelial cells. In addition, EXEL-2880 prevents anchorage-independent proliferation of tumor cells under both normoxic and hypoxic conditions. In vivo, these effects produce significant dose-dependent inhibition of tumor burden in an experimental model of lung metastasis. Collectively, these data indicate that EXEL-2880 may prevent tumor growth through a direct effect on tumor cell proliferation and by inhibition of invasion and angiogenesis mediated by HGF and VEGF receptors. [Cancer Res 2009;69(20):8009–16]

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-08-4889

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. F. V. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,652
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
Schmidt, L. S., Duh, F.-M. C., Chen, F., Kishida, T., Glenn, G. M., Choyke, P. L., Scherer, S. W., Zhuang, Z., Lubensky, I. A., Dean, M. C., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,517
Active and Inactive Protein Kinases: Structural Basis for Regulation
Johnson, L. N., Noble, M. E. M., & Owen, D. J. (1996) · Cell · doi:10.1016/s0092-8674(00)81092-2 · Cited by 1,396
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. K., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,361
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
Bergers, G., Song, S., Meyer-Morse, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317929 · Cited by 1,192
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Comoglio, P. M., Giordano, S., & Trusolino, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2530 · Cited by 832
Hepatocyte growth factor/ c-met signaling pathway is required for efficient liver regeneration and repair
Huh, C.-G., Factor, V. M., Sánchez, A., Uchida, K., Conner, E. A., & Thorgeirsson, S. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306068101 · Cited by 750
Biological behavior of malignant melanoma cells correlated to their survival in vivo.
Fidler, I. J. (1975) · PubMed · Cited by 592
The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas
Nakajima, M., SAWADA, H., Yamada, Y., Watanabe, A., Tatsumi, M., Yamashita, J., Matsuda, M., SAKAGUCHI, T., Hirao, T., & Nakano, H. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990501)85:9%3c1894::aid-cncr3%3e3.0.co;2-j · Cited by 494
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
Ma, P. C., Kijima, T., Maulik, G., Fox, E. A., Sattler, M., Griffin, J. D., Johnson, B. E., & Salgia, R. (2003) · PubMed · Cited by 454
Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor
Takayama, H., LaRochelle, W. J., Sharp, R., Otsuka, T., Kriebel, P., Anver, M. R., Aaronson, S. A., & Merlino, G. T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.701 · Cited by 442
Hepatocyte Growth Factor Enhances Vascular Endothelial Growth Factor-Induced Angiogenesis in Vitro and in Vivo
Xin, X., Yang, S., Ingle, G. S., Zlot, C. H., Rangell, L. K., Kowalski, J., SCHWALL, R. H., Ferrara, N., & Gerritsen, M. E. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64058-8 · Cited by 397
Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation.
Rong, S., Segal, S., Anver, M. R., Resau, J. H., & Woude, G. F. V. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4731 · Cited by 365
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas
Renzo, M. F. D., Olivero, M., Martone, T., Maffé, A., Maggiora, P., Stefani, A. D., Valente, G., Giordano, S., Cortesina, G., & Comoglio, P. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203455 · Cited by 334
A novel germ line juxtamembrane Met mutation in human gastric cancer
Lee, J., Han, S.-U., Cho, H., Jennings, B. A., Gerrard, B., Dean, M. C., Schmidt, L. S., Zbar, B., & Woude, G. F. V. (2000) · Oncogene · doi:10.1038/sj.onc.1203874 · Cited by 330
Frequent amplification of the c-met gene in scirrhous type stomach cancer
Kuniyasu, H., Yasui, W., Kitadai, Y., Yokozaki, H., Ito, H., & 田原, 榮. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)91548-5 · Cited by 329
A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo
Martens, T., Schmidt, N. O., Eckerich, C., Fillbrandt, R., Merchant, M. A., SCHWALL, R. H., Westphal, M., & Lamszus, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1418 · Cited by 310
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu
Lengyel, E. R., Prechtel, D., Resau, J. H., Gauger, K., Welk, A., Lindemann, K. Y., Salanti, G., Richter, T., Knudsen, B. S., Woude, G. F. V., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20598 · Cited by 275
Fully Human Monoclonal Antibodies to Hepatocyte Growth Factor with Therapeutic Potential against Hepatocyte Growth Factor/c-Met–Dependent Human Tumors
Burgess, T. L., Coxon, A., MEYER, S. R., Sun, J., Rex, K. L., Tsuruda, T. S., Chen, Q., Ho, S.-Y., Li, L. Z., Kaufman, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3329 · Cited by 252
Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas.
Park, W. S., Dong, S. M., Kim, S. Y., Na, E. Y., Shin, M. S., Pi, J. H., Kim, B. J., Bae, J. H., Hong, Y. K., Lee, K. S., et al. (1999) · PubMed · Cited by 251
The MET oncogene drives a genetic programme linking cancer to haemostasis
Boccaccio, C., Sabatino, G., Médico, E., Girolami, F., Follenzi, A., Reato, G., Sottile, A., Naldini, L., & Comoglio, P. M. (2005) · Nature · doi:10.1038/nature03357 · Cited by 250
Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models
Cao, B. B., Su, Y., Oskarsson, M. K., Zhao, P., Kort, E. J., Fisher, R. J., Wang, L.-M., & Woude, G. F. V. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131200498 · Cited by 213
In vivo targeting of SF/HGF and c‐met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis
Abounader, R., Lal, B., Luddy, C., Koe, G. S., Davidson, B. L., Rosen, E. M., & Laterra, J. (2001) · The FASEB Journal · doi:10.1096/fj.01-0421fje · Cited by 186
c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases
Zeng, Z., Weiser, M. R., Kuntz, E. J., Chen, C., Khan, S. A., Forslund, A., Nash, G. M., Gimbel, M. I., Yamaguchi, Y., Culliford, A. T., et al. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.049 · Cited by 181
Out of air is not out of action
Bottaro, D. P., & Liotta, L. A. (2003) · Nature · doi:10.1038/423593a · Cited by 175
Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity.
Bellusci, S., Moens, G., Gaudino, G., Comoglio, P. M., Nakamura, T., Thiery, J. P., & Jouanneau, J. (1994) · PubMed · Cited by 168
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a
Schiering, N., Knapp, S., Marconi, M., Flocco, M. M., Cui, J., Perego, R., Rusconi, L., & Cristiani, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1734128100 · Cited by 156
Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model.
Tomioka, D., Maehara, N., Kuba, K., Mizumoto, K., Tanaka, M., Matsumoto, K., & Nakamura, T. (2001) · PubMed · Cited by 151
c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations
Bellon, S. F., Kaplan‐Lefko, P. J., Yang, Y., Zhang, Y., Moriguchi, J., Rex, K. L., Johnson, C. W., Rose, P., Long, A. M., O'Connor, A. B., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705774200 · Cited by 140
Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents
Laird, A., & Cherrington, J. M. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.51 · Cited by 130
Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion.
Lorenzato, A., Olivero, M., Patanè, S., Rosso, E., OLIARO, A., Comoglio, P. M., & Renzo, M. F. D. (2002) · PubMed · Cited by 124
Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase
Wang, W., Marimuthu, A., Tsai, J. Y., Kumar, A., Krupka, H. I., Zhang, C., Powell, B., Suzuki, Y., Nguyen, H. T., Tabrizizad, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600048103 · Cited by 84
Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model.
Kim, S. J., Johnson, M., Koterba, K. L., Herynk, M. H., Uehara, H., & Gallick, G. E. (2003) · PubMed · Cited by 83
Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas
Baykal, C. M., Ayhan, A., Al, R. A., Yuce, K., & Ayhan, A. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(02)00073-2 · Cited by 77
Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors
Cai, Z., Wei, D. D., Schroeder, G. M., Cornelius, L. A. M., Kim, K., Chen, X., Schmidt, R. J., Williams, D. K., Tokarski, J. S., An, Y., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.04.047 · Cited by 66
Clinical Significance of c-met Oncogene Alterations in Human Colorectal Cancer
Umeki, K., Shiota, G., & Kawasaki, H. (1999) · Oncology · doi:10.1159/000011985 · Cited by 64
Detection and typing of human papillomavirus in cervical carcinomas in Russian women
van Muyden, R. C. P. A., ter Harmsel, B. W. A., Smedts, F. M. M., Hermans, J., Kuijpers, J. C., Райхлин, Н. Т., Petrov, S., Lebedev, A., Ramaekers, F. C. S., Trimbos, J. B. M. Z., et al. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990501)85:9 · Cited by 54
Increasing levels of MYC and MET co-amplification during tumor progression of a case of gastric cancer
Seruca, R., Suijkerbuijk, R. F., Gärtner, F., Criado, M. B., Veiga, I., Olde-Weghuis, D., David, L., Castedo, S. M. M. J., & Sobrinho-Simões, M. A. (1995) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(95)00033-l · Cited by 48
Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy
Stabile, L. P., Lyker, J. S., Huang, L., & Siegfried, J. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302169 · Cited by 47
Human papillomavirus infection, cervical dysplasia and invasive cervical cancer in Honduras: A case-control study
Ferrera, A., Velema, J. P., Figueroa, M., Bulnes, R., Toro, L. A., Claros, J. M., de Barahona, O., & Melchers, W. J. G. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990909)82:6 · Cited by 43
The clinical value of hepatocyte growth factor and its receptor—c-met for liver cancer patients with hepatectomy
Wu, F., WU, L., Zheng, S., Ding, W., Teng, L., Wang, Z., Ma, Z., & ZHAO, W. (2006) · Digestive and Liver Disease · doi:10.1016/j.dld.2006.03.007 · Cited by 42
Prognostic significance of hepatocyte growth factor and c‐MET expression in patients with diffuse large B‐cell lymphoma
Kawano, R., Ohshima, K., Karube, K., Yamaguchi, T., Kohno, S., Suzumiya, J., Kikuchi, M., & Tamura, K. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05197.x · Cited by 29
A Novel Orally Bioavailable Inhibitor of Kinase Insert Domain-Containing Receptor Induces Antiangiogenic Effects and Prevents Tumor Growth in Vivo
Sepp‐Lorenzino, L., Rands, E., Mao, X., Connolly, B., Shipman, J. M., Antanavage, J., Hill, S., Davis, L. J., Beck, S. C., Rickert, K. W., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2871 · Cited by 27
Evaluation of the tyrosine kinase domain of theMet Proto-oncogene in sporadic ovarian carcinomas
Tanyi, J. L., Tory, K., Rigó, J. J., Nagy, B., & Papp, Z. (1999) · Pathology & Oncology Research · doi:10.1053/paor.1999.0219 · Cited by 25
Missense Mutation of the MET Gene Detected in Human Glioma
Moon, Y.-W., Weil, R. J., Pack, S., Park, W.-S., Pak, E. D., Pham, T., Karkera, J. D., Kim, H.-K., Vortmeyer, A. O., Fuller, B. G., et al. (2000) · Modern Pathology · doi:10.1038/modpathol.3880177 · Cited by 22
SPORADIC BILATERAL PAPILLARY RENAL CARCINOMA EXHIBITING C-MET MUTATION IN THE LEFT KIDNEY TUMOR
Takaki, Y., Furihata, M., YOSHIKAWA, C., Kishida, T., Yao, M., & Shuin, T. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67735-x · Cited by 4

Sorted by citations

Targeting MET in cancer: rationale and progress
Gherardi, E., Birchmeier, W., Birchmeier, C., & Woude, G. V. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3205 · Cited by 1,420
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
Yakes, F. M., Chen, J., Tan, J., Yamaguchi, T., Shi, Y., Yu, P., Qian, F., Chu, F., Bentzien, F., Cancilla, B., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0264 · Cited by 1,350
Self-citation
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224
The “Cyclopropyl Fragment” is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules
Talele, T. T. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00472 · Cited by 1,056
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.010 · Cited by 923

See all 395

Authors: Qian, F., Engst, S., Yamaguchi, K., Yu, P., Won, K.-A., Mock, L., Lou, T., Tan, J., Li, C., Tam, D., Lougheed, J., Yakes, F. M., Bentzien, F., Xu, W., Zaks, T., Wooster, R., Greshock, J., & Joly, A. H.
Affiliations: Exelixis (United States) (US)
1Exelixis, Inc., South San Francisco, California and
GlaxoSmithKline (United States) (US)
ORCID: Yu, Peiwen
Lou, Tracy
Tan, Jenny
Li, Connie
Xu, Wei
Greshock, Joel
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2009-10-14
Volume: 69
Issue: 20
Pages: 8009-8016
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-08-4889
OpenAlex: W2130921495
Cited by: 350
References: 48
Citations by year: 2026: 11 · 2025: 9 · 2024: 18 · 2023: 24 · 2022: 14 · 2021: 25 · 2020: 20 · 2019: 12 · 2018: 13 · 2017: 26 · 2016: 17 · 2015: 31 · 2014: 20 · 2013: 44 · 2012: 27
FWCI: 8.87
Type: journal article
Language: en
Open access: closed
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
Keywords: MET receptor tyrosine kinase, hepatocyte growth factor, tyrosine kinase inhibitors, tumor invasion, lung metastasis, angiogenesis, tumor cell proliferation, hypoxia, endothelial cells, KIT, FLT3, PDGFRβ, Tie2
MeSH terms: Anilides, Animals, Cell Adhesion, Cell Movement, Cells, Cultured, Endothelium, Vascular, Enzyme-Linked Immunosorbent Assay, Female, Fibroblasts, Humans, Lung Neoplasms, Mice, Inbred BALB C, Mice, Nude, Neoplasm Invasiveness, Neoplasms, Experimental, Neovascularization, Pathologic, Phosphorylation, Quinolines, Umbilical Veins, Blotting, Western, Apoptosis, Hepatocyte Growth Factor, Proto-Oncogene Proteins c-met, Dermis, Receptors, Vascular Endothelial Growth Factor, Protein Kinase Inhibitors, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks